Immunocore Holdings plc
IMCR
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$33.05
Price-2.10%
-$0.71
1Y
Price
Market Cap
$1.668b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+4.0%
EBITDA Margin+0.8%
Net Profit Margin-5.0%
Free Cash Flow Margin+4.0%
EBITDA Margin+0.8%
Net Profit Margin-5.0%
Free Cash Flow MarginRevenue
$379.590m
+53.2%
1y CAGR+41.8%
3y CAGR+105.2%
5y CAGREarnings
-$28.263m
+30.7%
1y CAGR+9.9%
3y CAGR+26.4%
5y CAGREPS
-$0.57
+44.1%
1y CAGR+11.6%
3y CAGR+25.8%
5y CAGRBook Value
$396.564m
$1.103b
Assets$705.936m
Liabilities$43.275m
DebtDebt to Assets
3.9%
-5.7x
Debt to EBITDAFree Cash Flow
$2.948m
-85.9%
1y CAGR+316.6%
3y CAGR+253.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company